文献速递产科母胎医学

二甲双胍与胰岛素治疗妊娠期糖尿病的随机对照研究:血糖控制及母婴结局

Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-19

这项多中心、开放标签、平行臂随机临床试验在西班牙马拉加2家医院纳入200例需药物治疗的妊娠期糖尿病女性,随机分为二甲双胍组和胰岛素组各100例。结果显示两组平均空腹及餐后血糖无差异,但二甲双胍组午餐或晚餐后血糖显著更优,低血糖事件更少,孕期增重更少,引产率和剖宫产率更低,而新生儿结局两组相似。

要点

  • 二甲双胍组低血糖事件显著少于胰岛素组(17.7% vs 55.9%)。
  • 二甲双胍组引产率(45.7% vs 62.5%)和剖宫产率(27.6% vs 52.6%)显著更低。
  • 两组平均空腹及餐后血糖无差异,新生儿结局相似。

核心结论

  • 二甲双胍治疗在部分餐后血糖控制上优于胰岛素,低血糖风险更低,母体增重更少,且作为单一治疗失败率低。
  • 大多数产科和围产期结局在两组间相似。

研究设计与样本

  • 多中心、开放标签、平行臂随机临床试验,在西班牙马拉加2家医院进行。
  • 纳入200例需药物治疗的妊娠期糖尿病女性,随机分为二甲双胍组100例和胰岛素组100例。
  • 研究对象年龄18至45岁,处于妊娠中晚期,主要结局为血糖控制(平均血糖、餐前和餐后血糖)及低血糖事件,以及产科和围产期结局与并发症。
  • 分析基于意向性治疗原则。

主要发现

  • 两组平均空腹和餐后血糖无差异,但二甲双胍组午餐或晚餐后血糖显著更优。
  • 低血糖事件在胰岛素组显著更常见(55.9% vs 17.7%;OR=6.118;95%CI 3.134-11.944;P=.000)。
  • 二甲双胍组从入组至产前访视(36-37孕周)体重增加更少(1.35±3.21 vs 3.87±3.50 kg;P=.000)。
  • 二甲双胍组引产率(45.7% vs 62.5%;OR=0.506;95%CI 0.283-0.903;P=.029)和剖宫产率(27.6% vs 52.6%;OR=0.345;95%CI 0.187-0.625;P=.001)显著更低。
  • 平均出生体重、巨大儿、大于胎龄儿及新生儿并发症在两组间无差异。

临床怎么用

  • 对于生活方式干预未控制的妊娠期糖尿病,二甲双胍可作为胰岛素之外的药物治疗选择,尤其关注餐后血糖控制和减少低血糖风险。
  • 二甲双胍治疗与更低的引产率和剖宫产率相关,但需结合患者个体情况决策。

局限性

  • 开放标签设计可能引入偏倚。
  • 研究仅在西班牙2家医院进行,外推性需谨慎。
  • 样本量200例,可能不足以检测罕见新生儿结局差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational diabetes that is not properly controlled with diet has been commonly treated with insulin. In recent years, several studies have published that metformin can lead to, at least, similar obstetrical and perinatal outcomes as insulin. Nevertheless, not all clinical guidelines endorse its use, and clinical practice is heterogeneous. OBJECTIVE: This study aimed to test whether metformin could achieve the same glycemic control as insulin and similar obstetrical and perinatal results, with a good safety profile, in women with gestational diabetes that is not properly controlled with lifestyle changes. STUDY DESIGN: The metformin for gestational diabetes study was a multicenter, open-label, parallel arms, randomized clinical trial performed at 2 hospitals in Málaga (Spain), enrolling women with gestational diabetes who needed pharmacologic treatment. Women at the age of 18 to 45 years, in the second or third trimesters of pregnancy, were randomized to receive metformin or insulin (detemir or aspart). The main outcomes were (1) glycemic control (mean glycemia, preprandial and postprandial) and hypoglycemic episodes and (2) obstetrical and perinatal outcomes and complications (hypertensive disorders, type of labor, prematurity, macrosomia, large for gestational age, neonatal care unit admissions, respiratory distress syndrome, hypoglycemia, jaundice). Outcomes were analyzed on an intention-to-treat basis. RESULTS: Between October 2016 and June 2019, 200 women were randomized, 100 to the insulin-treated group and 100 to the metformin-treated group. Mean fasting and postprandial glycemia did not differ between groups, but postprandial glycemia was significantly better after lunch or dinner in the metformin-treated-group. Hypoglycemic episodes were significantly more common in the insulin-treated group (55.9% vs 17.7% on metformin; odds ratio, 6.118; 95% confidence interval, 3.134-11.944; P=.000). Women treated with metformin gained less weight from the enrollment to the prepartum visit (36-37 gestational weeks) (1.35±3.21 vs 3.87±3.50 kg; P=.000). Labor inductions (45.7% [metformin] vs 62.5% [insulin]; odds ratio, 0.506; 95% confidence interval, 0.283-0.903; P=.029) and cesarean deliveries (27.6% [metformin] vs 52.6% [insulin]; odds ratio, 0.345; 95% confidence interval, 0.187-0.625; P=.001) were significantly lower in the metformin-treated group. Mean birthweight, macrosomia, and large for gestational age and babies' complications were not different between treatment groups. The lower cesarean delivery rate for women treated with metformin was not associated with macrosomia, large or small for gestational age, or other complications of pregnancy. CONCLUSION: Metformin treatment was associated with a better postprandial glycemic control than insulin for some meals, a lower risk of hypoglycemic episodes, less maternal weight gain, and a low rate of failure as an isolated treatment. Most obstetrical and perinatal outcomes were similar between groups.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Picón-César MJ, Molina-Vega M, Suárez-Arana M, et al. Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial. Am J Obstet Gynecol. 2021. PMID: 33887240. doi:10.1016/j.ajog.2021.04.229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。